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Abstract
Aim: 
How can we convert biomarkers into reliable, validated laboratory tests?  GFR estimators 
exist for more than a century. The first utilitarian biomarkers were endogenously 
produced urea and creatinine. Clinicians then developed simple tests to determine 
whether or not renal tubular function was maintained. Are there faster and better tests 
that reflect decreased renal function and increased acute kidney injury (AKI) risk? 
Methods: 
We inspect earlier, and recently propagated biomarkers. Cystatin C reflects GFR and is 
not confounded by muscle mass. Direct GFR and plasma volume can now be measured 
acutely within 3 h. Better yet would be tests that give information before GFR decreases 
and prior to urea, creatinine, and cystatin C increases. Prospective tests identifying those 
persons likely to develop AKI would be helpful. Even more utilitarian would be a test that 
also suggests a therapeutic avenue.
Results:
A number of highly provocative biomarkers have recently been proposed. Moreover, the 
application of big data from huge electronic medical records promise new directions in 
identifying and dealing with AKI. 
Conclusions: 
Pipedreams are in the pipeline; the novel findings require immediate testing, verification, 
and perhaps application. Future research promises to make such dreams come true. 
Key words
Acute kidney injury, biomarkers, artificial intelligence
Introduction
Acute kidney injury (AKI) is defined by a rapid increase in serum (or plasma) 
creatinine, decrease in urine output, or both. AKI is common and occurs in approximately 
15% of patients admitted to hospital, while its incidence in intensive care units has been 
reported in more than half of patients with a substantial mortality. AKI is not a single 
disease, but instead consists of a loose syndrome collection of conditions including 
sepsis, cardiovascular causes, nephrotoxicity, urinary tract obstruction, and in short - 
anything that can cause glomerular filtration rate (GFR) to be reduced quickly.1 Can the 
condition be separated from reversible causes? The importance of delineating any A
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unknown acute decrease in renal function into “prerenal”, “renal”, and “postrenal” 
etiologies has not changed since the first renal biomarkers were described and remains 
the physician’s immediate obligation. 
The AKI time framework is 7 days. The current AKI definitions are based on two 
basic criteria: changes in serum creatinine and how much urine is made (oliguria or 
not?). From those two variables, we can stage AKI into stage 1 (creatinine >1.5 times 
baseline and/or urine volume <0.5 ml/kg for 6-12 h); stage 2 (creatinine >2 times 
baseline or urine volume <0.5 ml/kg for >12 h) or stage 3 (creatinine >3.0 times baseline 
or urine volume <0.3 ml/kg for >24 h). These definitions are of great value for 
classification (chart review) but not invariably helpful for physicians working with acutely 
ill patients. Creatinine is easily measured, while urine production rate is another matter. 
Choosing Wisely campaigns are aimed to advance a national dialogue on how to avoid 
unnecessary medical tests, treatments, and procedures. Can physicians receive help for 
their patients at the bedside or (very) shortly thereafter, particularly along the lines of 
“choosing wisely”? Biomarkers (better than creatinine) could be of assistance. Arguably, 
the first utilitarian marker for renal disease, AKI, AKD, or CKD, was proteinuria, which we 
generally attribute to Bright but was probably described a century earlier.2 What progress 
has been made in this area up to the present date (Figure 1)?
Assessment goals
Any clinical test, biomarkers included, requires addressing certain accepted 
standards. Sensitivity and specificity are terms used to evaluate a clinical test's utility 
(positive in disease, negative in health). They are independent on the population of 
interest. Positive and negative predictive values consider the clinical value of a test. 
These latter parameters are dependent on the prevalence of the disease in the 
population of interest. The sensitivity and specificity of a quantitative test are also subject 
to the cut-off value, above or below, which the test is positive. In general, the higher the 
sensitivity, the lower the specificity (and vice versa). Thereafter, receiver-operator 
characteristics (ROC) are commonly generated. ROC curves plot false positives against 
true positives for all cut- off values. The area under the curve (AUC) of a perfect test is 
1.0 (right angle) and that of a useless test, no better than tossing a coin (linear line). 
"Biomarkers" (albeit trendy) are not excused from these rigorous criteria.A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Glomerular filtration rate and other markers
Urea and creatinine
Non-protein nitrogen (urea, biuret, and ammonia) was an early marker, but quickly 
supplanted by urea (in the USA expressed as blood-urea nitrogen, BUN).3 Thereafter, 
creatinine soon followed. Van Slyke and colleagues developed the concept of 
"clearance" and in a remarkable paper compared the clearance of urea and creatinine to 
phenolsulfonphthalein (PSP) excretion in terms of utility.4 The authors observed that 
urea clearance falls below 50% of its normal value before blood creatinine content, blood 
urea content, or PSP excretion were altered. The group also observed a unique value in 
determining the urine (U) to plasma (P) ratio (U/P) to delineate certain conditions. Then 
how did creatinine obtain the vaunted position it holds today?
Rehberg first proposed the use of creatinine to monitor renal function.5 The 
measurement at the time was cumbersome in terms of overestimating serum creatinine 
at values <88 µmol/L, so Rehberg gave creatinine exogenously. We now know that 
creatinine is excreted slightly. Thus, Rehberg surely saturated the excretory tubular 
transporter, resulting in a highly accurate GFR estimate; however, Van Slyke had not yet 
suggested the clearance concept. Since Rehberg, the creatinine era extends to almost 
100 years of research and now GFR is estimated by various formulae (eGFR). The 
subject has been recently reviewed.6
Creatinine is a breakdown product of creatine phosphate from muscle and protein 
metabolism and is released at a constant rate, depending on the body's muscle mass 
(Figure 2A). Creatine kinase catalyzes the conversion to phosphocreatine. Formation of 
the anhydride, creatinine, occurs spontaneously during this process (Figure 2B). 
Creatinine is eliminated by glomerular filtration; however, very little or no reabsorption of 
creatinine occurs. There is modest tubular secretion, a fraction that relatively increases 
as GFR decreases. Since Smith, we know that inulin clearance is the gold standard for 
determining GFR,7 although renal or plasma clearance of chromium 51-labeled 
ethylenediaminetetraacetic acid (51Cr-EDTA), diethylenetriaminepentaacetic acid 
(DTPA), iohexol, and iothalamate are as good.8 
A glance at the relationship between GFR and serum creatinine (Figure 3A) 
discloses the fact that creatinine is very good when GFR is sharply reduced, but of lesser 
utility when renal function is largely preserved.9 As a result, GFR can be reduced by 
>50% before clinicians notice the elevation. Clinicians earlier relied on clever strategies A
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to circumvent confounders in patients with suspected AKI, particularly when urinary 
output decreased. Since urea is resorbed by the tubules in a flow-dependent manner 
(oliguria – increased urea absorption), volume depletion (pre-renal azotemia) should 
feature a sharper increase in plasma urea than creatinine. Measuring U/P urea and U/P 
creatinine was an early strategy to diagnose AKI, as was determining tubular function in 
terms of sodium reabsorption. With a single plasma (or serum) sample, coupled with a 
simultaneous urine sample (no timed collection is necessary), clinicians can distinguish 
between AKI and volume depletion by calculating the amount of sodium excreted per the 
amount filtered by dividing the clearance of sodium by the clearance of creatinine, 
namely the fractional excretion (FENa). Of course, these functional tests are confounded 
by diuretic treatment and the time interval of administration. A common indignant cause 
for nephrology consultation in any hospital is: “This patient refuses to respond to 
Lasix!” At that point, an intellectual confrontation with AKI is probably already too late. 
Urinary tract obstruction can now be ruled out in minutes with ultrasound. However, 
some care and clinical acumen is required in these diagnostic processes and therefore 
the search for more biomarkers continues.
Cystatin C
Cystatin C is a cysteine-protease inhibitor (molecular weight 13.3 kD) that is freely 
filtered but is degraded and/or resorbed in the renal tubule so that none appears in the 
urine. Since 1985, cystatin C has been suggested as marker of the renal function.10 The 
protease has a "house-keeping" function. Cystatin C is produced at a constant rate in all 
nucleated cells investigated to date, freely filtered in the renal glomeruli and reabsorbed, 
and catabolized in the proximal tubules. This catabolic process largely involves megalin. 
Jensen et al11 showed that cystatin C binds to megalin and cubulin with high affinity. 
Megalin deficient mice revealed an increased urinary excretion of cystatin C associated 
with defective uptake by endocytosis. In rats exposed to ischemia/reperfusion injury 
urinary cystatin C excretion was increased and associated with a focal decrease in 
proximal tubule endocytosis with no apparent change in megalin expression. These 
findings may be of relevance to clinical AKI.
Cystatin C avoids several confounding variables that plague other estimators of 
GFR. Creatinine is inaccurate at detecting mild renal impairment, and creatinine levels 
can vary with muscle mass but little (aside from body builders) with protein intake. Urea A
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levels might change with protein intake and are also urine flow rate dependent. Urea 
reabsorption is heavily dependent upon protein intake, hydration state, and tubular 
reabsorption as already observed by Van Slyke et al.4 Cystatin C side-steps these 
pitfalls. Direct comparisons of cystatin C- and creatinine-based prediction equations for 
eGFR, compared to a gold standard, have been made.12 In those studies, S-Cys C-
based prediction equations appeared to be more precise than those of S-Cr for those 
patients with measured GFR > 60 mL/min/1.73 m2 and could therefore be of benefit in 
the earlier detection of renal impairment in certain subpopulations.
But is cystatin C better than creatinine (Figure 3B-C)? Certainly not in cost that 
favors creatinine over cystatin C by a factor of 10 to 1. A direct comparison between 
cystatin C and creatinine has been published.9 Conceivably, in patients with reduced 
muscle mass because of amputations or in those with degenerative muscle disease, 
cystatin C might provide more accurate information compared to serum creatinine. 
Cystatin C may also play a role in assessing renal function in children or in the massively 
obese. However, as a biomarker, the idea that cystatin C beats creatinine (or urea for 
that matter) is difficult to defend. Finally, our clinical laboratory reports creatinine values 
within 20 min. Cystatin C levels (Figure 2C) require much more time.
GFR estimation at the bedside with a visible fluorescent injectate
Rizk and colleagues developed a novel method for rapid bedside GFR 
measurements that beats creatinine and cystatin C.13 Simultaneously, the authors 
estimated effective plasma volume. The markers consist of a rhodamine derivative and 
small 5-kD fluorescein carboxymethylated dextrans. After a single intravenous injection, 
both GFR and plasma volume are determined on the basis of the plasma 
pharmacokinetics of the rhodamine derivative and the fluorescein carboxymethylated 
dextrans, respectively. The authors relied on iohexol-measured GFR as the gold 
standard and achieved a correlation with visible fluorescent injectate GFR R2=0.99. The 
blood requirement was 1.5 ml and the time-frame 3 h. The added value here is the 
simultaneous determination of plasma volume, a value of substantial therapeutic 
importance. Whether or not this method should be employed as a screen in those at 
high risk or used when simpler biomarkers are suggestive of AKI remains to be 
determined. In any event, in intensive care units such a technique would clearly be more 
valuable than eGFR.A
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Markers that precede creatinine increases
The idea is that the kidneys react to stress or damage by releasing detectable 
products into the urine or plasma. Since so many mechanisms in the kidneys could be 
influenced, the candidates to examined are many. The presence of many candidates 
does not necessarily translate into better diagnostic strategies. But it does result in far 
more work. A schematic of candidates, tested or hypothetical (Figure 3), is formidable.
Numerous molecules have been identified as potential markers for early AKI 
detection before creatinine increases can be verified. An early candidate was N-acetyl-
beta-D-glucosaminidase (NAG). NAG is a hydrolytic lysosomal enzyme that is present in 
high concentrations in proximal tubular cell lysosomes. The NAG isoenzyme-B is 
associated to the lysosomal membrane and excreted in urine during tubular damage. 
Because of its stability in urine, its relatively large molecular mass which precludes 
filtration by the glomerulus and its presence in high activity in the tubular lysosomes, 
elevation of urinary NAG activity has been taken as a marker for renal proximal tubular 
damage or more precisely, loss of lysosomal integrity. Unfortunately, the threshold for 
release of tubular enzymes in response to injury may not lead to clinically apparent AKI 
is quite low.14 Therefore, urinary NAG has high sensitivity but low specificity for AKI.
Nephrocheck®
Tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor 
binding protein-? (IGFBP7) reflect cell-cycle arrest, a phenomenon occurring in proximal 
tubular cells under stress. TIMP-2 and IGFBP7 have been incorporated and 
commercialized (Astute Medical, San Diego, CA, USA) as a diagnostic test 
(Nephrocheck). The test gives results within 20 min and the markers peak at 6-24 h. 
Nephrocheck has been assessed in two single-center trials, leading to Food-and-Drug 
Administration (FDA) approval. Meersch et al randomized Nephrocheck-positive patients 
after cardiac surgery to receive specialized care including fluid management and the 
titration of vasoactive medications. The authors reported a reduction in established 
AKl.15 A similar care bundle was given to patients undergoing non-cardiac major surgery 
after testing positive for the biomarkers.16 In that study, the rates of moderate and severe 
AKI were significantly reduced with the intervention. The sample sizes in these studies 
were small. The need for renal replacement therapy, and mortality were not reduced. A
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The patients in both studies were at high risk. Nonetheless, the investigators were 
intrepid by simultaneously testing an intervention.
Kidney injury marker-1 (KIM-1)
KIM-1 is a type 1 transmembrane protein, with an immunoglobulin and mucin 
domain that is markedly up-regulated in the proximal tubule in the post-ischemic rat 
kidney. Kim-1 is an apoptotic-cell phagocytosis and scavenger receptor that is most 
highly upregulated in proximal tubular epithelium in acute and chronic kidney injury.17 
The ectodomain of KIM-1 is shed from cells. Han et al conducted studies to evaluate 
whether or not KIM-1 is present in human AKI and might serve as a urinary marker of 
acute renal tubular injury.18 They reported a soluble form KIM-1 in the urine of AKI 
patients. Since that report, the utility of KIM-1 in predicting AKI has been avidly pursued. 
KIM-1 has been most convincingly utilized to identify AKI in the course of drug therapies 
closely associated with AKI, such as cisplatin-induced nephrotoxicity. Urinary KIM-1 
levels are elevated in cisplatin induced AKI and may help in the differential diagnosis of 
proximal epithelial-cell injuries.19
Neutrophil gelatinase associated lipocalin (NGAL)
NGAL is a member of the lipocalin superfamily, 24p3, which induces the formation 
of renal epithelia.20 NGAL acts as a growth and differentiation factor in multiple cell 
types, including developing and mature renal epithelia, and some of this activity is 
enhanced in the presence of siderophore-iron complexes.21 The molecule is responsible 
for iron traffic within renal epithelia.22 Mishra et al used a transcriptome-wide 
interrogation strategy to identify renal genes that are induced very early after renal 
ischemia, whose protein products might serve as novel biomarkers for AKl.23 NGAL 
proved the most convincing. Since that time, NGAL has been a serious contender as a 
utilitarian biomarker for AKI that indeed supersedes creatinine. Nevertheless, 
weaknesses have been exposed and doubts as to NGAL's utility have been expressed 
(Figure 4).24 NGAL levels not only increase unpredictably during evolving AKI, but also 
during other chronic and acute inflammatory conditions frequently encountered in 
intensive care units. Such conditions include sepsis, recent coronary bypass surgery, 
and acute exacerbations of obstructive pulmonary diseases.A
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Liver-type fatty acid binding protein (L-FABP)
L-FABP is expressed in human proximal tubules and has an endogenous 
antioxidative function. L-FABP binds fatty acids and binds them to mitochondria or 
peroxisomes, where the fatty acids then undergo beta oxidation. L-FABP is expressed 
not only in the liver, but also in the intestine, pancreas, stomach, lung, and kidney.25 L-
FABP has been studied as a biomarker (ischemia-reperfusion, contrast-induced AKI, 
transplantation), as well as a potential ameliorating agent. For instance, Matsui et al 
investigated aristolochic-acid (Balkan nephropathy) nephrotoxicity.26 Since mice do not 
express L-FABP in kidney, the authors constructed a transgenic mouse that does so (hl-
FABP). Administration of aristolochic acid increased hl-FABP. These mice were 
protected from Balkan nephropathy compared to wild-type controls without hl-FABP. The 
novelty here is identifying a biomarker that also harbors a possible therapeutic potential.
Proenkefalin (PENK)
Enkephalins are opioid peptides that are found at high levels in the brain and 
endocrine tissues. Studies have shown that enkephalins play an important role in 
behavior, pain, cardiac function, cellular growth, immunity, and ischemic tolerance. 
PENK is an endogenous opioid polypeptide hormone, which via proteolyic cleavage, 
produces the enkephalin peptides [met]-enkephalin, and to a lesser extent, [leu]-
enkephalin. PENK is expressed in many tissues including the kidney.27 Beunders et al 
have proposed PENK as a novel biomarker for renal function.28 PENK plasma levels 
showed promise and were highly correlated with iohexol clearance. An influence of 
PENK on outcome was suggested by the authors but not documented.
Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1)
Chemokine (C-C motif) ligand 2 (CCL2) is a chemotactic cytokine that recruits 
monocytes, releases growth factors and promotes adhesion in vascular endothelium. 
The CCL2 molecule also recruits memory T cells, and dendritic cells to the sites of 
inflammation produced by either tissue injury or infection. Elevated serum and urinary 
CCL2 levels and expression of its receptor (CCR2) have been associated with 
tumorigenesis in human urinary-tract malignancies. The molecule is upregulated in 
ischemia-reperfusion injury. Moledina et al measured preoperative and postoperative A
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plasma MCP-1 levels in adults undergoing cardiac operations to evaluate the association 
of perioperative MCP-1 levels with acute kidney injury (AKI) and death. Translational 
Research Investigating Biomarker Endpoints in AKI (TRIBE-AKI) was a prospective, 
multicenter, observational cohort study.29 The authors reported that higher plasma MCP-
1 were associated with increased AKI and risk of death after cardiac operations. They 
suggest that MCP-1 could be used as a biomarker to identify high-risk patients for 
potential AKI prevention strategies in the setting of cardiac operations.
Dickkopf-3 (DKK-3)
The dickkopf (German fathead) Dkk gene family encodes secreted glycoproteins 
represented as four main members in vertebrates.30 The hallmark of the Dkk1/2/4 family 
is their ability to modulate Wnt signaling. Wnts, in turn, are an evolutionarily conserved 
family of growth factors, whose signaling is involved in numerous processes in 
development, organism maintenance, and disease. In the adult, DKKs are implicated in 
bone formation and bone disease, cancer, Alzheimer's disease, and now also AKI.
Zewinger et al hypothesized that DKK-3 might reflect stress-induced renal tubular 
epithelia and that the glycoprotein could provide information regarding the propensity of 
ongoing tubulo-interstitial disease and short-term eGFR loss.31 Thus, they actually 
investigated acute kidney disease (AKD) rather than AKI. First, they observed that DKK-
3-to-creatinine concentrations at baseline were higher in CKD patients than controls, 
supporting the idea that DKK-3 is produced in greater amounts in these patients. 
Furthermore, DKK-3 predicted the subsequent steepness in decline of eGFR in the 
patients. Thus, DKK-3 appeared to be a biomarker of persons particularly at risk for a 
rapidly declining GFR.
In a subsequent article, the group investigated any association between DKK-3, 
AKI, and subsequent renal functional decline in persons undergoing cardiac surgery.32 
The initial observational study from Saarland University included patients who had 
cardiac surgery forming a derivational cohort. Thereafter, the investigators studied 
patients who underwent cardiac surgery at the Cleveland Clinic (RenalRIP trial) forming 
a validation cohort. The authors found that compared to clinical and other laboratory 
measurements, urinary concentrations of DKK-3-to-creatinine determinations 
significantly improved AKI prediction in both cohorts. High urinary DKK-3-to-creatinine 
concentrations were independently associated with significantly lower renal function at A
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hospital discharge and reduced GFR after a median follow-up of 820 days. The authors 
concluded that preoperative urinary DKK-3 is an independent predictor of subsequent 
AKI risk and a further loss of renal function. Thus, the biomarker could predict AKI before 
any initiating event, a feature that is unique compared to other markers.
In experimental CKD models, DKK-3 promoted renal tubulointerstitial fibrosis 
through modulation of the canonical Wnt/-catenin signaling pathway.33 In clinical studies 
(above), increased urinary DKK3 levels identified patients at high risk for short-term CKD 
progression, regardless of the cause of kidney disease, baseline renal function, and 
albuminuria. A schematic of DKK-3 and kidney is shown (Figure 5).34
Soluble urokinase plasminogen activator receptor (suPAR)
Urokinase, also known as urokinase-type plasminogen activator (uPA) is a serine 
protease originally isolated from urine, but also present in blood and extracellular matrix. 
The primary substrate is plasminogen, which when cleaved to plasmin triggers a 
proteolytic cascade that participates in thrombolysis and/or extracellular matrix 
degradation. The urokinase receptor (CD87 or uPAR) is a multidornain glycoprotein, 
tethered to cell membranes via a glycosylphosphodidyl- inositol (GPI) anchor. The uPAR 
interacts with several other proteins, including vitronectin, the uPAR-associated protein 
(uPARAP), and the integrin family of membrane proteins. When When uPA is bound to 
the receptor, there is cleavage between the GPl-anchor and the uPAR, releasing soluble 
receptor (suPAR). The circulating suPAR is a marker of renal disease severity and 
aggressiveness and has become a biomarker for activation of the inflammatory and 
immune systems (Figure 6).35 
The investigators have shown earlier that circulating suPAR is involved in the 
pathogenesis of focal and segmental glomerulosclerosis and likely acts on podocytes by 
activating the av3 integrin on the cell surface.36 The group has also shown that the 
apolipoprotein L1 gene variants present in African Americans are dependent on plasma 
suPAR levels.37 APOL1 G1 or G2 genotypes augment av integrin activation and 
causes proteinuria in mice in a suPAR-dependent manner. The synergy suPAR and 
APOL1 G1 or G2 variants on av3 integrin activation is a mechanism for CKD.
In a recent tour-de-force, the group showed that suPAR is a marker for, and may 
be involved in the pathogenesis of, AKl.38 The investigators measured plasma levels of A
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suPAR pre-procedurally in patients who underwent coronary angiography (exploratory 
cohort) and patients who underwent cardiac surgery (confirmatory cohort) and at the 
time of admission to the intensive care unit in critically ill patients. Pre-procedural high 
suPAR levels were associated with AKI in the clinical studies, similar to the report 
involving DKK-3. This state-of-affairs was consistent across a variety of clinical 
subgroups. The data were underscored with a transgenic suPAR over-expressing mouse 
model that was subjected to iodinated contrast material. An anti-suPAR antibody 
ameliorated the effects. The suPAR molecule, binding to av3 integrin in a cell system, 
generated superoxide. The suPAR-treated cells also had a higher rate of non-
mitochondrial oxygen consumption, indicating an active involvement of other cellular 
oxygen-consuming reactions in addition to that catalyzed by the mitochondrial 
cytochrome C oxidase.
A prospective study to identify biomarkers (RUBY) 
A multi-center international prospective observational study to identify biomarkers 
of the persistence of stage 3 AKI as defined by the KDIGO criteria would appear highly 
desirable. The RUBY (not an eponym) was such an investigation. Patients in the 
intensive care unit (ICU) with moderate or severe AKI (KDIGO stage 2 or 3) were 
enrolled.39 A total of 336 patients could be analyzed. The authors selected potential 
candidate biomarkers from proteins associated with apoptosis, necrosis, endothelial 
injury, cell–cell and cell–matrix adhesion, cytoprotection, oxidative processes, cell-cycle 
regulation, inflammation, tubular injury, immune function, and fibrosis for biologic 
plausibility. Urinary C–C motif chemokine ligand 14 (CCL14) was the most predictive of 
persistent stage 3 AKI with an area under the receiver operating characteristic curve 
(AUC) of 0.95. As a matter of fact, CCL14 beat CH13L1, plasma cystatin C, plasma 
proenkephalin, urinary NGAL, and urinary L-FABP.
CCL14 is a member of the chemokine family of small molecules that were initially 
recognized for roles in leukocyte chemotaxis and are implicated in tissue injury and 
repair processes. CCL14 (HCC-1) belongs to the CC chemokine family. CCL14 activates 
monocytes but does not induce chemotaxis. Could CCL14 be a mediator of AKI and 
non-recovery? A possibility might be that inflammatory (such as tumor necrosis factor- 
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and others) signals from injured tubules, release CCL14. Such a state-of-affairs could 
promote further Th1 inflammatory signals. 
Whither to now?
If one's own knowledge is not enough, perhaps artificial intelligence could help.40 
A retrospective cohort study was conducted in medical, surgical, and mixed ICUs at 
Mayo Clinic in Rochester, Minnesota. The investigators stated their primary objective as 
predicting AKI using extant clinical data following ICU admission. They incorporated 
known AKI risk factors and routinely measured vital characteristics and laboratory 
results. The model achieved an AUC of 0.88 on validation. The results suggest a 
sensitivity of 92%, a specificity of 68% and detected 30% of AKI cases at least 6 h 
before the standard time criteria (AKI stages 1-3). For discrimination of AKI stages 2 to 
3, the model had 91% sensitivity, 71% specificity, and 53% detection of AKI cases at 
least 6 hours before AKI onset. The idea here is to apply a self-improvable modifiable 
algorithm to improve AKI diagnoses. Such algorithms could incorporate all biomarkers 
known to date.
This idea has been carried much further. Tomasev et al developed a deep 
learning approach for the continuous risk prediction of future AKI deterioration in 
patients.41 They built their AKI model on recent work that incorporates adverse events 
from electronic health records. Their model was developed on a large, longitudinal, 
dataset of electronic health records (US Veterans Administration Electronic Health 
Records) that covers diverse clinical environments, comprising 703,782 adult patients 
across 172 inpatient locations and 1,062 outpatient sites. The model predicted 56% of all 
inpatient episodes AKI, and 90% of all AKI episodes that required subsequent 
administration of dialysis, with a lead time of up to 48 h and a ratio of 2 false alerts for 
every true alert. All of this remarkable result was without any of the biomarkers 
mentioned here.
Conclusions
The “elephant-in-the-room” question is: “Does this biomarker research improve 
outcomes?” The answer is, “it might!” Research from future prospective clinical studies 
should help us further. Investigators must settle upon a “gold-standard” test and then 
compare the new candidates in terms of performance with the Bland-Altman plot A
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statistic. Improved phenotyping of the patients is mandatory, which requires a utilitarian 
electronic medical records system. Particularly exciting are putative biomarkers that have 
direct therapeutic implications.
Prospective studies such as the RUBY study are mandatory.39 Haase-Fielitz and 
colleagues recently tested the notion that drawing attention to AKI might improve care.41 
Hospitalized patients with increasing creatinine values meeting KDIGO guidelines for AKI 
were randomized into those identified with an early warning computerized message 
recommending a nephrology consult and supplied with an AKI identifier or to usual care. 
The nephrologists confirmed the diagnosis, made medication recommendations (usually 
to discontinue), optimized circulating fluid volume, and arranged for follow-up. Compared 
to usual care, AKI complications were reduced, diagnoses were more commonly 
established, and potentially deleterious medications discontinued. This study defines 
how creatinine (the gold standard) stacks up. Now, the investigators are in a position to 
test other markers against this standard in a prospective fashion. In that way, robust 
statistics can be applied and the markers tested against creatinine. 
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Figure legends
Fig. 1. Shown is a nephron along which putative "biomarkers" are approximately located. 
Hope is it that these products arrive in the urine before clinical evidence of decreased 
GFR (increase in serum creatinine) is apparent. All are dependent upon urine 
production. Thus, oliguria is a strong confounder.
Fig. 2. The pivotal enzyme, creatine phosphokinase, metabolizes substrates to 
phosphocreatine and to the by-product, creatinine (A). As a result, an anhydride (loss of 
water) is formed that we term "creatinine" (B). The daily-produced product is freely 
filtered, nonprotein bound, and appears in the urine. The resorption is essentially zero 
and the secretion is (relatively) trivial. 
Fig. 3. The relationship between serum creatinine and glomerular filtration rate (renal 
work) is hyperbolic (A). Therefore, lower concentrations are of lesser value in accurately 
reflecting GFR than higher concentrations. Cystatin C has some advantages over 
creatinine in selected populations (B). However, cystatin C shows similar limitations to 
creatinine in those subjects with largely-preserved renal function. Cystatin C (ribbon 
diagram) is a "second-generation" GFR marker, also endogenously produced (C). This 
marker is produced by our total (nuclear-containing) cell mass (adapted from Porrini et 
al.9).
Fig. 4. Many studies suggest that NGAL levels in urine or plasma can be regarded as a 
biomarker for AKI. Under normal conditions, NGAL levels are relatively low in urine and 
plasma. However, NGAL levels in AKI patients increase rapidly from basal levels to 
quickly reach diagnostic levels. However, NGAL has numerous sources, several 
interacting partners, and relies on megalin for urinary clearance. The complexity is 
illustrated by the fact that urinary NGAL levels may also predict the progression of CKD 
(Adapted from Martennson and Bellamo.24).
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Fig. 5. Urinary DKK3 is a biomarker of ongoing renal tubular cell injury, i.e. a renal 
tubular cell 'stress' indicator within the 'kidney injury continuum'. ECM, extracellular 
matrix (Adapted from Schunk et al.34).
Fig. 6. (A) Schematic of the structure of uPAR, the mechanism of cleavage and the 
formation of suPAR. D1, D2, and D3 represent the three homologous domains of 
suPAR. (B) The suPAR molecule binds to av3 integrin. In a human proximal tubular cell 
line, suPAR had profound effects on mitochondrial respiration and resulted in superoxide 
production (adapted from Hayek et al.37). 
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